Evaluation of Biomarkers in Egyptian Patients with Different Grades of Nonalcoholic Fatty Liver Disease

Borai, Ibrahim H.; Shaker, Yehia; Kamal, Maha Moustafa; Ezzat, Wafaa M.; Ashour, Esmat; Afify, Mie; Gouda, Weaam; Elbrashy, Maha M.

doi:10.14218/jcth.2017.00004

Cited by 11 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it is difficult in some cases to differentiate liver fibrosis from fatty liver which is a common condition among the Egyptian population particularly HCV patients. 41,42 Further, MR elastography (MRE) appears to be the most reliable method for grading liver fibrosis. 43 TE and MRE have comparable accuracy for detecting significant fibrosis.…”

Section: Discussionmentioning

confidence: 99%

Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt

El‐Wahab

Ayoub

Shorbila

et al. 2020

Clinical Epidemiology and Global Health

View full text Add to dashboard Cite

Background: The scale of HCV problem in Egypt prioritized the development of a national control strategy that employs the use of locally manufactured generic direct-acting antivirals (DAAs). Achieving sustained virologic response in chronic HCV patients is the key for preventing fibrosis progression and ultimately its resolution. Objective(s): To evaluate impact of generic DAAs on liver fibrosis in chronic HCV patients using some noninvasive biomarkers (NIBMs). Methods: A total of 280 chronic HCV patients (18 treatment experienced and 262 naive) were enrolled and received the standard of care. All patients were clinically evaluated before starting treatment and at 4, 12 and 24 weeks of treatment. Results: The sensitivity and the specificity of the tested NIBMs for predicting cirrhosis versus liver ultrasound ranged between 75.0-79.6% and 59.4-67.2% respectively. All NIBMs showed significant linear decline during the treatment and follow up periods among responders but tended to fluctuate in values toward an increase among non-responders. In cox regression analysis, normal baseline ALT, AST, total serum cholesterol, serum albumin, WBCS, prothrombin activity and early stages of liver fibrosis predicted improvement in liver fibrosis by 1.5-2 folds. The mean probability of recovery at 1, 3, 6 months varied between the different scores and ranged from 0.059 to 0.637, 0.125-0.741, 0.538-0.951 respectively. Conclusion:The results provide prognostic data on the improvement in liver fibrosis over the treatment course and follow up periods without the need for a liver biopsy. Early detection and management of HCV infection should be emphasized to maximize the benefits of the treatment. Recently many noninvasive biomarkers (NIBMs) for assessing liver fibrosis have been developed, and are frequently used in clinical

show abstract

Section: Discussionmentioning

confidence: 99%

Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt

El‐Wahab

Ayoub

Shorbila

et al. 2020

Clinical Epidemiology and Global Health

View full text Add to dashboard Cite

show abstract

“…In addition, NASH patients who had been treated with cenicriviroc, an inhibitor of hepatic macrophages, which secrete large amounts of proinflammatory cytokines, showed an amelioration of their histopathologic signs, including hepatic fibrosis [ 8 ]. Recent animal studies have demonstrated that proinflammatory cytokines such as transforming growth factor beta (TGFB) [ 9 ] and IL18 are involved in the development of NAFLD [ 10 ]. However, it is still unclear whether mouse models of NASH, featuring liver fibrosis, show high expression of these proinflammatory cytokines.…”

Section: Introductionmentioning

confidence: 99%

Consumption of barley ameliorates the diabetic steatohepatitis and reduces the high transforming growth factor β expression in mice grown in α-minimum essential medium in vitro as embryos

Ishiyama

Kimura

Umihira

et al. 2021

Biochemistry and Biophysics Reports

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD), which includes the subtype non-alcoholic steatohepatitis (NASH), is a major complication of type 2 diabetic mellitus (T2DM), even among non-obese patients. However, the exact cause of NAFLD/NASH in non-obese patients with T2DM is unclear. We studied a non-obese mouse model of T2DM created through the malnourishment of embryos by culture in vitro for 48 h in α-minimum essential medium (MEM) at the two-cell stage. We compared the development of steatohepatitis in these MEM mice with control mice that were similarly cultured in standard potassium simplex-optimized medium (KSOM). We also studied the effects of 10 weeks of consumption of barley, which contains large amounts of the soluble fiber β-glucan, on the steatohepatitis of the adult MEM mice. The size of lipid droplets, the area of fibrosis, and the mRNA expression of the transforming growth factor beta ( Tgfb ) gene in the liver were higher in adult MEM mice fed a rice-based diet than in KSOM mice fed the same diet. However, barley consumption reduced the area of fibrosis and TGFB expression in MEM mice. In conclusion, adult mice that are cultured in MEM at the two-cell embryo stage develop steatohepatitis and T2DM, accompanied by higher hepatic TGFB expression, than KSOM controls. Furthermore, the consumption of barley during adulthood ameliorates the steatohepatitis and reduces the TGFB expression.

show abstract

“…fatty liver diseases. Based on specific criteria, the severity of NAFLD was classified as absent, mild NAFLD (Liver echogen slightly increased, good visualization of intrahepatic vessels and diaphragms), moderate NAFLD (Increased liver echogenicity, disappearance of intrahepatic vascular echo lines) and severe NAFLD (Significant increase in liver echogenicity, poor penetration of the right hepatic lobe, and blurred vision of the diaphragm) (38,39). After obtaining written and informed consent, peripheral blood and liver tissues were collected from 30 healthy volunteers, 30 mild NAFLD patients and 30 severe NAFLD patients.…”

Section: Samples Of Peripheral Blood and Liver Tissues Of Patients Withmentioning

confidence: 99%

Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling

Jie

Wang

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

Non‑alcoholic fatty liver disease (NAFLD), which affects approximately one‑third of the general population, has become a global health problem. Thus, more effective treatments for NAFLD are urgently required. In the present study, high levels of C‑C motif ligand 19 (CCL19), signaling pathways such as Toll‑like receptor 4 (TLR4)/nuclear factor‑κB (NF‑κB), and proinflammatory factors including interleukin‑6 (IL‑6) and tumor necrosis factor‑α (TNF‑α) were detected in NAFLD patients, thereby indicating that there may be an association between CCL19 and these factors in NAFLD progression. Using a high‑fat diet (HFD), the present study generated a Sprague‑Dawley rat model of NAFLD, which displayed dyslipidemia with increased levels of plasma aspartate aminotransferase, alanine aminotransferase, total cholesterol and triglyceride. Dyslipidemia, liver histopathology and gene expression analyses indicated that the NAFLD model was successfully induced by HFD, and metformin and berberine (BBR) were effective treatments for NAFLD. HFD‑induced CCL19 levels and associated factors were markedly reduced by the two drug treatments. In addition, metformin or BBR alone significantly promoted adenosine monophosphate‑activated protein kinase (AMPK) phosphorylation, which was inhibited by HFD. These results demonstrated that metformin and BBR could improve NAFLD, which may be via the activation of AMPK signaling, and the high expression of CCL19 in NAFLD was significantly reduced by metformin and BBR. It could be inferred that inhibition of CCL19 may be an effective treatment for NAFLD.

show abstract

Evaluation of Biomarkers in Egyptian Patients with Different Grades of Nonalcoholic Fatty Liver Disease

Cited by 11 publications

References 40 publications

Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt

Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt

Consumption of barley ameliorates the diabetic steatohepatitis and reduces the high transforming growth factor β expression in mice grown in α-minimum essential medium in vitro as embryos

Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling

Contact Info

Product

Resources

About